Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label, multicohort, phase II KEYNOTE-158 study (NCT02628067)....

Descripción completa

Detalles Bibliográficos
Autores principales: O'Malley, David M., Bariani, Giovanni Mendonca, Cassier, Philippe A., Marabelle, Aurelien, Hansen, Aaron R., De Jesus Acosta, Ana, Miller, Wilson H., Safra, Tamar, Italiano, Antoine, Mileshkin, Linda, Xu, Lei, Jin, Fan, Norwood, Kevin, Maio, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887941/
https://www.ncbi.nlm.nih.gov/pubmed/34990208
http://dx.doi.org/10.1200/JCO.21.01874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887941/
https://www.ncbi.nlm.nih.gov/pubmed/34990208
http://dx.doi.org/10.1200/JCO.21.01874

Ejemplares similares